Additional Supporting Information may be found in the online version of this article.

STEM_1355_sm_SuppFig1.tif1950KSupplemental Fig.1. Expression of bimodal imaging transgenes using engineered lentiviral and retroviral vectors. (A) A self-inactivating lentiviral and retroviral transfer vectors, both bearing an IRES-GFP element, were used to construct the following vectors: LV-TK, LVTR [20], RV-GFl, RV-TK and RV-TR under the CMV promoter. (B) Serial dilutions of mMSC-TK cells expressing GFP-Fluc (mMSC-TK-GFl) were plated and 24hrs later Fluc signal intensity was determined. Plot shows direct correlation between mMSC-TK-GFl cell number and Fluc signal intensity. Abbreviations: CMV, cytomegalovirus promoter; Fluc, firefly luciferase; IRES, Internal ribosomal entry site; GFl, green fluorescent protein and firefly luciferase fusion; TK, Thymidine Kinase; TRAIL, tumor necrosis factor apoptosis-inducing ligand.
STEM_1355_sm_SuppFig2.tif1745KSupplemental Fig.2. hMSC-TR-TK have antitumor effect and can be eliminated post tumor treatment in vitro. U87-FmC cells were co-cultured with different proportions of hMSCTR (grey columns) or hMSC-TR-TK (black columns) and two days later, GCV (10μg/mL) was added to the cultures. (A) Plot shows the activation of Caspase-3/7 in the co-cultures with U87- FmC and engineered hMSC at day one. (B) Plot shows U87-FmC viability measured by Fluc signal in co-culture conditions at day three. (C-G) U87-FmC were co-cultured with engineered hMSC-TR-GFl or hMSC-TR-TK-GFl and two days later GCV (10μg/mL) was added to the cultures. Photomicrographs (original magnification, x4) show hMSC GFP+ cells at day three post GCV treatment (C-F). (G) Plot shows % of viability of modified hMSC-Fluc cells measured by Fluc signal at day three. Bars, +SD. In all panels, *, p < .05 versus controls. Abbreviations: hMSC, human mesenchymal stem cells; GCV, ganciclovir; TK, Thymidine Kinase; TR, tumor necrosis factor apoptosis-inducing ligand; Fluc, firefly luciferase; GFl, green fluorescent protein and Fluc fusion.
STEM_1355_sm_SuppFig3.tif407KSupplemental Fig.3. Intratumorally implantation and fate of mMSC-TR-TK. Gli36vIII-FmC bearing mice were intratumorally implanted with mMSC-TR-TK. Photomicrographs of mice brain sections showing presence of therapeutic mMSC-TR-TK (green) in GBM tumors (mcherry) after 4 days post mMSC implantation (A). Photomicrographs of mice brain sections showing CD31 staining (red) and mMSC-TR-TK (green) at day 32 post-implantation (B). (Original magnification, x10 left panel and x20 right panel).
STEM_1355_sm_SuppInfo.pdf106KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.